Leap Therapeutics
LPTX
About: Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
Employees: 52
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more call options, than puts
Call options by funds: $11K | Put options by funds: $11K
4% less funds holding
Funds holding: 45 [Q1] → 43 (-2) [Q2]
7.25% less ownership
Funds ownership: 40.46% [Q1] → 33.21% (-7.25%) [Q2]
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
20% less capital invested
Capital invested by funds: $5.09M [Q1] → $4.09M (-$1M) [Q2]
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Financial journalist opinion
